Skip to main content

REVIEW article

Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1469830
This article is part of the Research Topic Multi-omics Application in Exploring Potential Biomarkers Targeting Resistance of Anti-Cancer Drugs View all 14 articles

The Role of SIRT1 in Autophagy and Drug Resistance: Unveiling New Targets and Potential biomarkers in Cancer Therapy

Provisionally accepted
Yujing Tang Yujing Tang 1,2Wantao Ju Wantao Ju 1,2Liu Yanjun Liu Yanjun 1,2Qin Deng Qin Deng 3*
  • 1 Southwest Jiaotong University, Chengdu, Sichuan Province, China
  • 2 Chengdu Third People's Hospital, Chengdu, Sichuan Province, China
  • 3 Second Affiliated Hospital, Chongqing Medical University, Chongqing, China

The final, formatted version of the article will be published soon.

    Cancer, the world's second leading cause of death after cardiovascular diseases, is characterized by hallmarks such as uncontrolled cell growth, metastasis, angiogenesis, hypoxia, and resistance to therapy. Autophagy, a cellular process that can both support and inhibit cancer progression, plays a critical role in cancer development and progression. This process involves the formation of autophagosomes that ultimately fuse with lysosomes to degrade cellular components. A key regulator of this process is Sirtuin 1 (SIRT1), which significantly influences autophagy. This review delves into the role of SIRT1 in modulating autophagy and its broader impacts on carcinogenesis. SIRT1 regulates crucial autophagy mediators, such as AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR), effectively promoting or suppressing autophagy. Beyond its direct effects on autophagy, SIRT1's regulatory actions extend to other cell death processes, including apoptosis and ferroptosis, thereby influencing tumor cell proliferation, metastasis, and chemotherapy responses. These insights underscore the complex interplay between SIRT1 and autophagy, with significant implications for cancer therapy. Targeting SIRT1 and its associated pathways presents a promising strategy to manipulate autophagy in cancer treatment. This review underscores the potential of SIRT1 as a therapeutic target, opening new avenues for enhancing cancer treatment efficacy.

    Keywords: Autophagy, Apoptosis, ferroptosis, Drug Resistance, Sirtuin family, SIRT1

    Received: 24 Jul 2024; Accepted: 13 Sep 2024.

    Copyright: © 2024 Tang, Ju, Yanjun and Deng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Qin Deng, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.